Abstract: The invention relates to a process for inhibiting the infection of influenza viruses and a polypeptide or protein medicine used therein. More particularly, the invention involves a process for inhibiting the highly pathogenic avian influenza virus (such as H5N1 subtype) infection and human influenza virus (such as H1N1 subtype and H3N2 subtype) infection, as well as the polypeptide or protein involved therein, and a polynucleotide encoding the polypeptide or protein and a vector or host cell expressing said polypeptide or protein.

Abstract: The invention relates to a process for inhibiting the infection of influenza viruses and a polypeptide or protein medicine used therein. More particularly, the invention involves a process for inhibiting the highly pathogenic avian influenza virus (such as H5N1 subtype) infection and human influenza virus (such as H1N1 subtype and H3N2 subtype) infection, as well as the polypeptide or protein involved therein, and a polynucleotide encoding the polypeptide or protein and a vector or host cell expressing said polypeptide or protein.

Abstract: The present invention relates to a recombinant soluble T cell receptor. The T cell receptor (TCR) is refolded and comprises a recombinant TCR &agr; or &ggr; chain extracellular domain having a first heterologous C-terminal dimerisation peptide; and a recombinant TCR &bgr; or &dgr; chain extracellular domain having a second C-terminal dimerisation peptide which is specifically heterodimerised with the first dimerisation peptide to form a heterodimerisation domain, which may be a coiled coil domain. The invention also provides nucleic acid sequences encoding the recombinant TCR and a method for producing the recombinant TCR.